Give equal importance to both raw material and formulation businesses, and promote both endogenous growth and external expansion; Continuously consolidating the foundation of characteristic active pharmaceutical ingredients, vigorously developing the formulation business, further improving the product line layout in the field of anticoagulation, and becoming a deep cultivator in the field of segmented treatment.

Taking nuclear medicine as the new core competitiveness of the enterprise, we aim to improve the domestic nuclear medicine network layout and create a full value industrial chain platform for nuclear medicine by exploring upstream, integrating downstream, and laying out cutting-edge development ideas.

Increase R&D investment, enhance R&D capabilities, focus on the development of innovative drugs in the fields of malignant tumors, neurodegenerative diseases, and cardiovascular and cerebrovascular diseases, introduce and develop the latest diagnostic and therapeutic nuclear drug products, and benefit the vast number of patients.